TAI'AN, China, March 3 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management team will present at the Rodman & Renshaw Annual China Investment Conference March 7 to 9, 2010 in Beijing, China.
The date, time and location of China Biologic's presentation at the Rodman & Renshaw Annual China Investment Conference are as follows:
During the conference, management will be available for one-on-one meetings with institutional investors. Interested parties please contact Lily Khaykina at LK@rodm.com or (212) 430-1714. Participation in the R&R Conference is by invitation only.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.
CONTACT: Mr. Y. Tristan Kuo, Chief Financial Officer of China Biologic
Products, Inc., +86-538-6202206, IR@chinabiologic.com; or Investors, Ms.
Lei Huang, Account Manager, +1-646-833-3417, lei.huang@ccgir.com, or
Crocker Coulson, President, +1-646-213-1915, crocker.coulson@ccgir.com,
both of CCG Investor Relations
Web site: http://www.chinabiologic.com/
http://www.ccgirasia.com/
